Amgen Receives Positive CHMP Opinion for Vectibix in Combination With Chemotherapy

Amgen AMGN today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending that Vectibix be approved for use in the European Union in first-line in combination with FOLFOX and in second-line in combination with FOLFIRI in patients who have received first-line fluoropyrimidine-based chemotherapy for patients with wild-type KRAS metastatic colorectal cancer, following a successful re-examination procedure by Amgen.